跳到主要內容

臺灣博碩士論文加值系統

(100.28.227.63) 您好!臺灣時間:2024/06/16 20:22
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:葉仲鏮
研究生(外文):Chung-Kang Yeh
論文名稱:過氧化氫誘導克隆5及熱休克蛋白60是肝細胞癌惡性進展的重要因子
論文名稱(外文):Hydrogen peroxide inducible clone-5 and heat shock protein 60 are malignant factors for hepatocellular carcinoma progression
指導教授:吳文陞
指導教授(外文):Wen-Sheng Wu
口試委員:胡志棠張瑞宜
口試日期:2020-07-31
學位類別:碩士
校院名稱:慈濟大學
系所名稱:醫學生物技術碩士班
學門:醫藥衛生學門
學類:醫學技術及檢驗學類
論文種類:學術論文
論文出版年:2020
畢業學年度:108
語文別:中文
論文頁數:29
中文關鍵詞:肝細胞癌過氧化氫誘導克隆 5熱休克蛋白 60癌瑞格
外文關鍵詞:HCCHic-5HSP60Regorafenib
相關次數:
  • 被引用被引用:0
  • 點閱點閱:111
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
肝細胞癌(HCC)是全球癌症排名前三名,在台灣是惡性腫瘤死亡
率排名第二名的癌症。高復發率是肝細胞癌預後不佳最主要的原因, 主要是由於肝癌細胞肝內、肝外的移轉所造成。因此了解肝癌移轉的 分子機轉是防治肝癌移轉的重要基礎。我們實驗室過去研究發現,過 氧化氫誘導克隆5(Hic-5)與熱休克蛋白(HSP60)在肝癌移轉扮演重要 角色,並且 Hic-5 在肝癌移轉組織中含量上都比正常組織要來的高, 顯示 Hic-5 與肝癌移轉的高度相關性,然而以往許多研究中 HSP60 與 肝癌移轉的相關性則較不明確。並且截至目前為止,亦尚未有針對肝 癌患者血液中 Hic-5 與 HSP60 濃度分析之相關研究。本研究中我們收 集臨床肝癌患者血清,使用分子酵素結合免疫吸附分析法 ( ELISA ) 檢測來自不同肝癌患者血液中 Hic-5 與 HSP60 濃度。實驗結果顯示, 以肝癌有無惡性進展區分成兩組,其血液中 Hic-5 高度表達與肝癌惡 性進展有顯著相關 ( P-value < 0.05 ) ,而 HSP60 若有測到濃度 皆反映肝癌為惡性進展 ( n=5 ) 。此外,以肝癌的二線用藥癌瑞格 ( Regorafenib ),處理來自肝癌患者的肝癌細胞株,發現 Regorafenib 在抑制肝癌細胞生長及移動的同時,Hic-5也跟著下降。 總而言之,本研究發現 Hic-5 及 HSP60 有希望成為非侵入性肝細胞 癌惡性進程的臨床新檢驗項目,並提出血液 Hic-5 及 HSP60 濃度反映
IV肝細胞癌惡性進展之模型。此外,Hic-5 亦可做為肝癌治療療效之指 標。
Hepatocellular carcinoma (HCC) is among the top three types of
cancer worldwide and is ranked second in the rate of death in people having malignant tumors in Taiwan. High recurrence rate is the main cause of poor prognosis of HCC mainly due to intrahepatic and extrahepatic metastasis of liver cancer cells. Accordingly, understanding the molecular mechanism of liver cancer metastasis is an important basis for preventing and treating liver cancer metastasis to understand the molecular mechanism of liver cancer metastasis. In the past studies our laboratory found that Hydrogen peroxide inducible clone-5 (Hic-5) and Heat shock protein 60 (HSP60) play important roles in liver cancer metastasis and Hic-5 is higher in tissues of metastatic liver cancer than in nonmetastatic liver cancer, suggesting a high correlation between Hic-5 and liver cancer metastasis. However, many of the past studies do not clearly indicate the correlation between HSP60 and liver cancer metastasis. Moreover there has not been any study so far specifically on the analysis of concentration of Hic-5 and HSP60 in the blood of the liver cancer patients. In this study, we collect serum from clinical liver cancer patients, and analyzing the concentrations of Hic-5 and HSP60 in the blood of different liver cancer patients using molecular enzyme-linked immunosorbent assay (ELISA). Experimental results show that, by dividing the patients in two groups based on whether the liver cancer has malignant progression, it is highly indicated that the Hic-5 in blood thereof is significantly correlated with malignant progression of liver cancer (P-value < 0.05). Regarding HSP60, if any concentration thereof is
VIdetected, reflects malignant progression of liver cancer (n=5). In addition, using Regorafenib which is a second-line drug for liver cancer for treating hepatoma cells from patients with liver cancer it was found that Regorafenib inhibited the growth and movement of liver cancer cells while concentration of Hic-5 also declined. In sum, in this study we found that Hic-5 and HSP60 are expected to become new clinical testing items for malignant process of non-invasive HCC and proposed a model of concentration of Hic-5 and HSP60 in blood reflecting the malignant progression of HCC. Moreover, Hic-5 can be used as an indicator of the efficacy of liver cancer treatment.
目錄
致謝 …………………………………………………………... I 中文摘要 …………………………………………………….IV Abstract ………………………………………………………VI 縮寫對照表 ………………………………………………VIII 目錄 ………………………………………………………IX 表目錄 ………………………………………………………X 圖目錄 …………………………………………………....... XI 第一章 研究背景及目的(Introduction)……………………… 1 1.1 研究背景…………………………………………..…1 1.2 研究目的……………………………………………..4 第二章 研究方法及進行步驟 (Materials & Methods)…..…..5
第三章 結果與討論(Results & Discussion)……………….…13 第四章 結論(Conclusion)…………………………………….17 第五章 參考文獻(Reference)…………………….…………..19 IX表目錄
表 1. HCC血清Hic-5、HSP60 濃度與病理切片報告整合
分析表……………………………………..……….... 21
表 2. 製作ROC Curve 基本資料…………….…………... 22
X圖目錄
圖 1. Malignant & Non malignant 分組中位數統計分析.23 圖 2. 血清Hic-5 與肝癌惡化相關性之 ROC Curve…..... 24 圖 3. Hic-5 在肝癌組織免疫染色……...……….………... 25 圖 4. 倒立光學顯微鏡下HCC340、HCC413 呈現不同細胞 型態…………………………………………...…….. 26
圖 5. HCC413 MTT 讀值…………………………………. 27 圖 6. HCC340、HCC413 使用Regorafenib 藥物進行細胞移 動之測定…………………………….……………… 28 圖 7. HCC340、HCC413 使用Regorafenib 測試Hic-5….29
第五章 參考文獻 1. 2. 3. 4.
Tang, Z., Hepatocellular Carcinoma-Cause, Treatment and Metastasis. World journal of gastroenterology : WJG, 2001. 7: p. 445-54.
Nakashima, O. and M. Kojiro, Recurrence of hepatocellular carcinoma: multicentric occurrence or intrahepatic metastasis? A viewpoint in terms of pathology. J Hepatobiliary Pancreat Surg, 2001. 8(5): p. 404-9.
Tang, Z.Y., et al., A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2004. 130(4): p. 187-96.
Deakin, N.O. and C.E. Turner, Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. 2011. 22(3): p. 327341.
5. Wu, J.R., et al., Hydrogen peroxide inducible clone-5 mediates reactive oxygen species signaling for hepatocellular carcinoma progression. Oncotarget, 2015. 6(32): p. 32526-44.
6. 7.
Pignatelli, J., et al., Hic-5 promotes invadopodia formation and invasion during TGF-β–induced epithelial–mesenchymal transition. Journal of Cell Biology, 2012. 197(3): p. 421-437.
Sheta, R., et al., Hic-5 regulates epithelial to mesenchymal transition in ovarian cancer cells in a TGFβ1-independent manner. Oncotarget, 2017. 8(47): p. 82506-82530.
8. Wu, J.-R., et al., Hydrogen peroxide inducible clone-5 sustains NADPH oxidasedependent reactive oxygen species-c-jun N-terminal kinase signaling in hepatocellular carcinoma. Oncogenesis, 2019. 8(8): p. 40.
9.
Chen, Y., X. Li, and S. Shao, The Clinical Value of HSP60 in Digestive System Cancers: a Systematic Review and Meta-Analysis. Clin Lab, 2019. 65(10).
10. Huang, Y.H., et al., Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol Carcinog, 2018. 57(9): p. 1087-1101.
11.
Thillai, K., K. Srikandarajah, and P. Ross, Regorafenib as treatment for patients with advanced hepatocellular cancer. Future Oncology, 2017. 13(25): p. 22232232.
12. 呂濟宇, et al., A Highly Sensitive Method for the Analysis of Long-Chain Free Fatty Acids in Yogurt by High Performance Liquid Chromatography with Fluorimetric Detection. 2009. 61(4): p. 65-72.
13. 林子軒。「Snail 調節肝癌細胞中MMP9 和 ZEB1 基因表達的轉錄機制」。 19碩士論文,慈濟大學醫學檢驗生物技術學系醫學生物技術碩士班, 2012。<https://hdl.handle.net/11296/8wfn9q>。
14. 謝佳倫。「登革病毒透過套膜蛋白區域三及抗甲型非結構蛋白抗體所誘發 之病理反應」。碩士論文,慈濟大學分子生物暨人類遺傳學系碩士班, 2014。<https://hdl.handle.net/11296/y6526s>。
15. 馬珮羚。「利用 LZ8 以阻斷 c-Met 依賴及非依賴的訊息來抑制肝癌轉移的 臨床前測試」。碩士論文,慈濟大學醫學檢驗生物技術學系醫學生物技術 碩士班,2014。<https://hdl.handle.net/11296/r83j6d>。
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊